132 related articles for article (PubMed ID: 38017624)
1. The Danish-Norwegian randomized trial on beta-blocker therapy after myocardial infarction: Design, rationale, and baseline characteristics.
Kristensen AMD; Munkhaugen J; Halvorsen S; Olsen MH; Bakken A; Sehested TSG; Ruddox V; Lange T; Fagerland MW; Torp-Pedersen C; Prescott E; Atar D
Eur Heart J Cardiovasc Pharmacother; 2024 May; 10(3):175-183. PubMed ID: 38017624
[TBL] [Abstract][Full Text] [Related]
2. Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial.
Kristensen AMD; Bovin A; Zwisler AD; Cerquira C; Torp-Pedersen C; Bøtker HE; Gustafsson I; Veien KT; Thomsen KK; Olsen MH; Larsen ML; Nielsen OW; Hildebrandt P; Foghmar S; Jensen SE; Lange T; Sehested T; Jernberg T; Atar D; Ibanez B; Prescott E
Trials; 2020 May; 21(1):415. PubMed ID: 32446298
[TBL] [Abstract][Full Text] [Related]
3. BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study.
Munkhaugen J; Ruddox V; Halvorsen S; Dammen T; Fagerland MW; Hernæs KH; Vethe NT; Prescott E; Jensen SE; Rødevand O; Jortveit J; Bendz B; Schirmer H; Køber L; Bøtker HE; Larsen AI; Vikenes K; Steigen T; Wiseth R; Pedersen T; Edvardsen T; Otterstad JE; Atar D
Am Heart J; 2019 Feb; 208():37-46. PubMed ID: 30530121
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).
Rossello X; Raposeiras-Roubin S; Latini R; Dominguez-Rodriguez A; Barrabés JA; Sánchez PL; Anguita M; Fernández-Vázquez F; Pascual-Figal D; De la Torre Hernandez JM; Ferraro S; Vetrano A; Pérez-Rivera JA; Prada-Delgado O; Escalera N; Staszewsky L; Pizarro G; Agüero J; Pocock S; Ottani F; Fuster V; Ibáñez B;
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):291-301. PubMed ID: 34351426
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis.
Maqsood MH; Alam M; Atar D; Birnbaum Y
J Cardiovasc Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 33136764
[TBL] [Abstract][Full Text] [Related]
6. Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation Myocardial Infarction With Preserved Systolic Function? A Meta-Analysis.
Misumida N; Harjai K; Kernis S; Kanei Y
J Cardiovasc Pharmacol Ther; 2016 May; 21(3):280-5. PubMed ID: 26424094
[TBL] [Abstract][Full Text] [Related]
7. Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality: a Swedish nationwide observational study.
Mohammad MA; Andell P; Koul S; Desta L; Jernberg T; Omerovic E; Spaak J; Fröbert O; Jensen J; Engstrøm T; Hofman-Bang C; Persson H; Erlinge D
EuroIntervention; 2017 Jun; 13(2):e210-e218. PubMed ID: 28242589
[TBL] [Abstract][Full Text] [Related]
8. Effects of Long-Term Carvedilol Therapy in Patients With ST-Segment Elevation Myocardial Infarction and Mildly Reduced Left Ventricular Ejection Fraction.
Amano M; Izumi C; Watanabe H; Ozasa N; Morimoto T; Bingyuan B; Suwa S; Miyake M; Tamura T; Nakagawa Y; Kadota K; Inuzuka Y; Minamimoto Y; Furukawa Y; Kaji S; Suzuki T; Akao M; Inada T; Kimura T;
Am J Cardiol; 2023 Jul; 199():50-58. PubMed ID: 37245250
[TBL] [Abstract][Full Text] [Related]
9. The effect of carvedilol in patients with impaired left ventricular systolic function following an acute myocardial infarction. How do the treatment effects on total mortality and recurrent myocardial infarction in CAPRICORN compare with previous beta-blocker trials?
Otterstad JE; Ford I
Eur J Heart Fail; 2002 Aug; 4(4):501-6. PubMed ID: 12167391
[TBL] [Abstract][Full Text] [Related]
10. βeta blocker interruption after uncomplicated myocardial infarction: rationale and design of the randomized ABYSS trial.
Silvain J; Cayla G; Ferrari E; Range G; Puymirat E; Delarche N; Collet JP; Dumaine R; Slama M; Payot L; Kasty ME; Aacha K; Vicaut E; Montalescot G;
Am Heart J; 2023 Apr; 258():168-176. PubMed ID: 36682596
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and tolerability of administration of granulocyte colony-stimulating factor on left ventricular function in patients with myocardial infarction: a meta-analysis of randomized controlled trials.
Kang S; Yang Y; Li CJ; Gao R
Clin Ther; 2007 Nov; 29(11):2406-18. PubMed ID: 18158081
[TBL] [Abstract][Full Text] [Related]
12. Effects of Compound Danshen Dripping Pills on Ventricular Remodeling and Cardiac Function after Acute Anterior Wall ST-Segment Elevation Myocardial Infarction (CODE-AAMI): Protocol for a Randomized Placebo-Controlled Trial.
Wu YJ; Deng B; Wang SB; Qiao R; Zhang XW; Lu Y; Wang L; Gu SZ; Zhang YQ; Li KQ; Yu ZL; Wu LX; Zhao SB; Zhou SL; Yang Y; Wang LS
Chin J Integr Med; 2023 Dec; 29(12):1059-1065. PubMed ID: 37656413
[TBL] [Abstract][Full Text] [Related]
13. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
Figtree GA; Vernon ST; Hadziosmanovic N; Sundström J; Alfredsson J; Arnott C; Delatour V; Leósdóttir M; Hagström E
Lancet; 2021 Mar; 397(10279):1085-1094. PubMed ID: 33711294
[TBL] [Abstract][Full Text] [Related]
14. Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
Nordenskjöld AM; Agewall S; Atar D; Baron T; Beltrame J; Bergström O; Erlinge D; Gale CP; López-Pais J; Jernberg T; Johansson P; Ravn-Fisher A; Reynolds HR; Somaratne JB; Tornvall P; Lindahl B
Am Heart J; 2021 Jan; 231():96-104. PubMed ID: 33203618
[TBL] [Abstract][Full Text] [Related]
15. Effect of oral β-blocker treatment on mortality in contemporary post-myocardial infarction patients: a systematic review and meta-analysis.
Dahl Aarvik M; Sandven I; Dondo TB; Gale CP; Ruddox V; Munkhaugen J; Atar D; Otterstad JE
Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):12-20. PubMed ID: 30192930
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Beta-Blocker Therapy after Myocardial Infarction in the Reperfusion Era: A Systematic Review.
Hong J; Barry AR
Pharmacotherapy; 2018 May; 38(5):546-554. PubMed ID: 29601115
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Outcomes with or without Beta-Blocker Therapy After Acute Myocardial Infarction in Patients Without Heart Failure or Left Ventricular Systolic Dysfunction (from the Acute Coronary Syndromes Israeli Survey [ACSIS]).
El Nasasra A; Beigel R; Klempfner R; Alnsasra H; Matetzky S; Iakobishvili Z; Rubinshtein R; Halabi M; Blatt A; Zahger D
Am J Cardiol; 2021 Mar; 143():1-6. PubMed ID: 33359228
[TBL] [Abstract][Full Text] [Related]
18. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Watanabe H; Ozasa N; Morimoto T; Shiomi H; Bingyuan B; Suwa S; Nakagawa Y; Izumi C; Kadota K; Ikeguchi S; Hibi K; Furukawa Y; Kaji S; Suzuki T; Akao M; Inada T; Hayashi Y; Nanasato M; Okutsu M; Kametani R; Sone T; Sugimura Y; Kawai K; Abe M; Kaneko H; Nakamura S; Kimura T;
PLoS One; 2018; 13(8):e0199347. PubMed ID: 30153268
[TBL] [Abstract][Full Text] [Related]
19. A randomized multicenter trial to evaluate early invasive strategy for patients with acute ST-segment elevation myocardial infarction presenting 24-48 hours from symptom onset: Protocol of the RESCUE-MI study.
Gao W; Zhong X; Ma Y; Huang D; Wang R; Zhao S; Yang S; Qian J; Ge J
Am Heart J; 2022 Sep; 251():54-60. PubMed ID: 35525262
[TBL] [Abstract][Full Text] [Related]
20. Beta-blockers for suspected or diagnosed acute myocardial infarction.
Safi S; Sethi NJ; Nielsen EE; Feinberg J; Jakobsen JC; Gluud C
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012484. PubMed ID: 31845756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
